In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.83 million on Dec 02 ’24. In the deal valued at $55.10 per share,15,000 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 181,540 shares worth roughly $7.45 million.
Then, Kulkarni Samarth sold 30,000 shares, generating $1,668,678 in total proceeds. Upon selling the shares at $55.62, the Chief Executive Officer now owns 196,540 shares.
Before that, KASINGER JAMES R. sold 1,089 shares. CRISPR Therapeutics AG shares valued at $50,399 were divested by the General Counsel and Secretary at a price of $46.28 per share. As a result of the transaction, KASINGER JAMES R. now holds 62,597 shares, worth roughly $2.57 million.
Needham reiterated its CRISPR Therapeutics AG [CRSP] rating to a Buy in a research note published on August 06, 2024; the price target was $84. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. Wolfe Research started covering the stock on February 15, 2024. It rated CRSP as “a Peer perform”.
Price Performance Review of CRSP
On Friday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -0.99% to $41.02. Over the last five days, the stock has lost -0.12%. CRISPR Therapeutics AG shares have risen nearly 4.22% since the year began. Nevertheless, the stocks have fallen -34.43% over the past one year. While a 52-week high of $91.10 was reached on 01/03/25, a 52-week low of $38.20 was recorded on 01/02/25. SMA at 50 days reached $47.12, while 200 days put it at $52.48.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 40.45, which if violated will result in even more drops to 39.88. On the upside, there is a resistance level at 41.84. A further resistance level may holdings at 42.66. The Relative Strength Index (RSI) on the 14-day chart is 40.58, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.50%. Stochastics %K at 27.98% indicates the stock is a holding.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2024-12-13, dropping by -1.27 million shares to a total of 18.12 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 19.39 million shares. There was a decline of -7.03%, which implies that there is a negative sentiment for the stock.
